Voy­ager shares spike on an ear­ly glimpse of promise for Parkin­son’s gene ther­a­py

Shares of Voy­ager Ther­a­peu­tics $VY­GR took off in af­ter-mar­ket trad­ing on Wednes­day af­ter the biotech spot­light­ed signs of suc­cess from a small num­ber of pa­tients treat­ed with their gene ther­a­py for Parkin­son’s.

This once-off gene treat­ment is de­signed to amp up the ef­fec­tive­ness of lev­odopa, giv­ing pa­tients back bet­ter mo­tor con­trol that is lost as the dis­ease pro­gress­es, while cut­ting back on the dosage they have to take to man­age the dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER